Century Therapeutics, INC Form 4 insider transactions

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, received significant equity awards, including 135,000 restricted stock units and options for 265,000 shares.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, received significant equity grants including restricted stock units and stock options.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, received 110,000 restricted stock units and options for 225,000 shares.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, disposed of 1,611 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, acquired 58,060 shares of common stock at $0.8483 per share.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, acquired 52,000 shares of common stock at a weighted average price of $0.5837.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, disposed of 463 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics, Inc. granted Director Lee Han Myung 88,000 stock options with a $0.592 exercise price, vesting over 36 months.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 257 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, sold 526 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, sold 5,462 shares of common stock to cover tax withholding obligations related to RSU vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, filed a Form 4 indicating a planned purchase of 35,000 shares of common stock on November 19, 2025, at a weighted average price of $0.4951, with all profits from the transaction to be disgorged to the issuer.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, sold 32,456 shares of common stock to cover tax withholding obligations related to RSU vesting.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 292 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, was granted 762,543 restricted stock units, vesting over two years.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, sold 263 shares to cover tax withholding from restricted stock unit vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, sold 488 shares of common stock to cover tax withholding obligations related to RSU vesting.

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, sold 539 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, was granted 1,587,614 restricted stock units, vesting over two years.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, sold 296 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Kimberly Blackwell, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.60 per share, as disclosed in a recent SEC Form 4 filing.

Century Therapeutics, Inc. Director Joseph Jimenez was granted 44,000 stock options with an exercise price of $0.60, vesting based on continued service.

Alessandro Riva, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.6 per share, as disclosed in a recent SEC Form 4 filing.

Century Therapeutics, Inc. Director Carlo Rizzuto was granted 44,000 stock options with an exercise price of $0.60, vesting on the earlier of June 12, 2026, or the next annual meeting of stockholders.

Century Therapeutics, Inc. Director Daphne Quimi was granted 44,000 stock options with an exercise price of $0.6 per share, vesting over approximately one year.

Cynthia M. Butitta, a Director at Century Therapeutics, Inc., was granted 44,000 stock options with an exercise price of $0.60, vesting over approximately one year.

Century Therapeutics, Inc. Director Timothy P. Walbert has acquired 44,000 stock options at an exercise price of $0.60, vesting by June 12, 2026, or the next annual meeting.

Douglas Carr, SVP Finance & Operations at Century Therapeutics, Inc., sold 4,904 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Century Therapeutics' Chief Operations Officer, Adrienne Farid, sold 552 shares of common stock on June 9, 2025, at $0.622 per share, a non-discretionary transaction to cover tax withholding obligations related to the vesting of restricted stock units.

Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., sold 475 shares of common stock for tax withholding purposes related to restricted stock unit vesting.